TY  - JOUR

T1  - Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)

JO  - Journal of Clinical Oncology

PY  - 2007/06/20

AU  - Hanrahan EO

AU  - Lin HY

AU  - Du DZ

AU  - Yan S

AU  - Kim ES

AU  - Lee JJ

AU  - Ryan AJ

AU  - Tran HT

AU  - Johnson BE

AU  - Heymach JV

ED  - 

DO  - DOI: 10.1200/jco.2007.25.18_suppl.7593

PB  - American Society of Clinical Oncology (ASCO)

VL  - 25

IS  - 18_suppl

SP  - 7593

EP  - 7593

Y2  - 2026/03/02

ER  -